Search results
Showing 91 to 105 of 168 results for fibrosis
2 diabetes mellitus or metabolic syndrome. Untreated it can progress to fibrosis, cirrhosis and hepatocellular cancer. In most patients...
Our forward view highlights the topics we will prioritise in the coming year.
Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)
Evidence-based recommendations on ombitasvir–paritaprevir–ritonavir (also known as Viekirax) with or without dasabuvir (also known as Exviera) for adults with some types (called genotypes) of chronic hepatitis C.
Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making
This guideline covers diagnosing and managing age-related macular degeneration (AMD) in adults. It aims to improve the speed at which people are diagnosed and treated to prevent loss of sight.
Read biographies of the members of our quality standards advisory committee.
Read biographies of the members of our quality standards advisory committee.
Past technology appraisal appeals and decisions
NICE has developed a medtech innovation briefing (MIB) on Smart One for measuring lung function .
In development Reference number: GID-HST10067 Expected publication date: 19 August 2026
Plozasiran for treating familial chylomicronaemia syndrome [ID6593]
In development Reference number: GID-TA11793 Expected publication date: 18 November 2026
In development Reference number: GID-TA11819 Expected publication date: 03 September 2026
Olezarsen for treating familial chylomicronaemia syndrome [ID6585]
In development Reference number: GID-TA11678 Expected publication date: 19 August 2026
for people with cystic fibrosis? Any explanatory notes(if applicable) Why this is important- People with cystic fibrosis...
Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]
Discontinued Reference number: GID-TA11041